TY - JOUR
T1 - The Impact on COVID-19 by Intravenous Bevacizumab Used for Hereditary Hemorrhagic Telangiectasia
T2 - A Case Report
AU - Fanning, Ryan Patrick
AU - Strout, Sara
AU - Rowan, Nicholas R.
AU - Weiss, Clifford R.
AU - Galiatsatos, Panagis
N1 - Publisher Copyright:
© This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
PY - 2022/6
Y1 - 2022/6
N2 - Coronavirus disease 2019 (COVID-19) continues as an infectious pandemic. With emphasis on mitigating its impact globally, strategies have been emphasized on prevention to treatment in severe cases. As for pharmacotherapies, many have been researched, with a few being recommended for patients with COVID-19 depending upon their severity. Bevacizumab, a recombinant monoclonal antibody often used for oncological disease and rare genetic disorders, has gained attention in combatting COVID-19 due to the pharmacotherapy’s ability to inhibit vascular endothelial growth factor A (VEGF-A). VEGF has been identified as significantly upregulated in the lungs of persons who have died of COVID-19, raising interest for VEGF to be a potential target for patients with COVID-19. We present a case of a patient who was admitted due to complications of a rare genetic disorder, called hereditary hemorrhagic telangiectasia (HHT), warranting intravenous bevacizumab, who subsequently was diagnosed with COVID-19 pneumonia. We discuss the patient’s outcome and contribute to the growing potential of bevacizumab in the treatment of COVID-19.
AB - Coronavirus disease 2019 (COVID-19) continues as an infectious pandemic. With emphasis on mitigating its impact globally, strategies have been emphasized on prevention to treatment in severe cases. As for pharmacotherapies, many have been researched, with a few being recommended for patients with COVID-19 depending upon their severity. Bevacizumab, a recombinant monoclonal antibody often used for oncological disease and rare genetic disorders, has gained attention in combatting COVID-19 due to the pharmacotherapy’s ability to inhibit vascular endothelial growth factor A (VEGF-A). VEGF has been identified as significantly upregulated in the lungs of persons who have died of COVID-19, raising interest for VEGF to be a potential target for patients with COVID-19. We present a case of a patient who was admitted due to complications of a rare genetic disorder, called hereditary hemorrhagic telangiectasia (HHT), warranting intravenous bevacizumab, who subsequently was diagnosed with COVID-19 pneumonia. We discuss the patient’s outcome and contribute to the growing potential of bevacizumab in the treatment of COVID-19.
KW - Bevacizumab
KW - Covid-19
KW - Hereditary hemorrhagic telangiectasia
UR - http://www.scopus.com/inward/record.url?scp=85132530681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132530681&partnerID=8YFLogxK
U2 - 10.14740/jmc3948
DO - 10.14740/jmc3948
M3 - Article
C2 - 35837077
AN - SCOPUS:85132530681
SN - 1923-4155
VL - 13
SP - 307
EP - 311
JO - Journal of Medical Cases
JF - Journal of Medical Cases
IS - 6
ER -